THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Tuesday, H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to ...

Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected Ebvallo, a T cell therapy approved in Europe for a transplant-related blood ...

Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The ...

In a regulatory filing, Atara Biotherapeutics (ATRA) disclosed that on January 27, the company announced a reduction in its workforce that will impact approximately 50% of its current employees.

Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug candidate. Atara Biotherapeutics' headquarters in Thousand Oaks. The share ...

Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug candidate. Atara Biotherapeutics' headquarters in Thousand Oaks. The ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:ATRA) concerning possible violations of federal ...